Strong Protection by Bazedoxifene Against Chemically-Induced Ferroptotic Neuronal Death In Vitro and In Vivo

Xiangyu Hao, Yifan Wang, Yong Xiao Yang, Li‐Xi Liao, Tongxiang Chen, Pan Wang, Xiaojun Chen, Bao Ting ZhubioRxiv 2024 · DOI

TL;DR

Researchers have discovered that Bazedoxifene (BAZ), an FDA-approved drug for osteoporosis, provides powerful neuroprotection against ferroptosis—a specific type of iron-dependent cell death. Crucially, BAZ works by directly binding to and inhibiting the enzyme Protein Disulfide Isomerase (PDI), a mechanism that is entirely independent of its well-known role as an estrogen receptor modulator.

What Problem Does This Paper Address?

Ferroptosis is a form of regulated cell death driven by the accumulation of iron and the subsequent "rusting" of cellular lipids (lipid peroxidation). It has been implicated in a wide range of devastating conditions, including neurodegenerative diseases, stroke, and certain cancers.

While Bazedoxifene was already known to have neuroprotective effects in humans, the underlying mechanism was a mystery. Most researchers assumed it worked through estrogen receptors (ERs). However, relying on ER-mediated pathways limits a drug's utility, particularly for male patients or in tissues where ER expression is low. This paper investigates whether BAZ utilizes an alternative, ER-independent pathway to stop ferroptosis by targeting PDI, a protein that helps fold other proteins but can inadvertently trigger oxidative stress when overactive.

Methods

The authors employed a multi-disciplinary approach to validate their hypothesis:

  • Cellular Assays: They tested BAZ's protective power in several cell lines, including mouse hippocampal neurons (HT22) and ER-negative human breast cancer cells (MDA-MB-231), to prove the effect was ER-independent.
  • Target Engagement: To prove BAZ actually sticks to PDI, they used Surface Plasmon Resonance (SPR) to measure binding affinity and Cellular Thermal Shift Assays (CETSA) to observe the protein's stability in live cells.
  • Computational Modeling: They used molecular docking and 100-nanosecond Molecular Dynamics (MD) simulations to map the exact "pocket" where BAZ binds to PDI.
  • Biochemical Validation: They used site-directed mutagenesis to change a single amino acid (His256) in PDI, testing if this abolished BAZ's inhibitory effect.
  • In Vivo Testing: They used a mouse model where kainic acid (KA) was injected into the brain to induce hippocampal damage and memory deficits, then treated the mice with BAZ to measure recovery.

Datasets

As a biological study, the "datasets" consist of specific cell lines and structural models:

  • Cell Lines: HT22 (mouse neurons), MDA-MB-231 (ER-negative human breast cancer), BRL-3A (rat liver), and H9C2 (rat heart).
  • Protein Structures: The study utilized the crystal structure of human PDI (PDB code: 6I7S) and the chemical structure of BAZ (PDB code: 6PSJ).
  • Animal Models: Male C57BL/6 mice (used to avoid the confounding effects of fluctuating endogenous estrogen in females).

Key Insights and Ideas

  • The PDI-NOS Connection: The most significant "aha moment" is the discovery that PDI facilitates the dimerization (pairing up) of nitric oxide synthase (nNOS and iNOS). When these enzymes dimerize, they produce nitric oxide (NO), which fuels the production of reactive oxygen species (ROS) and leads to ferroptosis. BAZ breaks this chain by inhibiting PDI.
  • ER-Independent Protection: BAZ provided 100% protection in ER-negative cells. This confirms that its neuroprotective "day job" is separate from its "side hustle" as an estrogen mimic.
  • The His256 Anchor: Computational and mutational analysis identified Histidine 256 in the PDI $b'$ domain as the critical binding site. Mutating this single residue prevented BAZ from inhibiting the enzyme's activity.
  • Dual-Action Defense: Beyond PDI inhibition, BAZ also acts as a direct radical-trapping antioxidant, providing a two-pronged defense against lipid peroxidation.

Key Results

  • High Potency: In vitro, BAZ achieved 100% protection against ferroptosis-inducing chemicals (erastin and RSL3) at nanomolar concentrations (500 nM and 125 nM, respectively).
  • Strong Binding: SPR analysis revealed a very high binding affinity between BAZ and PDI, with a $K_d$ of approximately 3.3–3.6 nM.
  • Memory Rescue: In the mouse model, kainic acid dropped the "alternation rate" (a measure of working memory) to 50%. BAZ treatment restored this to roughly 65%, significantly mitigating cognitive decline.
  • Tissue Preservation: Histological staining (Fluoro-Jade B and TUNEL) showed that BAZ drastically reduced the number of degenerating and dying neurons in the CA3 region of the hippocampus.

Limitations and Future Work

The authors acknowledge that while kainic acid-induced death closely resembles ferroptosis, it is not an identical match to chronic neurodegenerative diseases like Alzheimer's. Future studies should test BAZ in more specific disease models.

Additionally, while the study focuses on PDI (PDIA1), there are many other members of the PDI family. It remains to be seen if BAZ interacts with these other isoforms. Finally, because BAZ is already FDA-approved for other uses, the path to clinical trials for neuroprotection is shorter, but human-specific dosing for brain health still needs to be established.

Summary updated

Abstract

ABSTRACT Ferroptosis is a form of regulated cell death characterized by excessive iron-dependent lipid peroxidation. Ferroptosis can be induced in cultured cells by exposure to certain chemicals ( e.g. , erastin and RSL3). Recently it was shown that protein disulfide isomerase (PDI) is a mediator of chemically-induced ferroptosis and also a target for ferroptosis protection. In this study, we find that bazedoxifene (BAZ), a selective estrogen receptor modulator with reported neuroprotective actions in humans, can inhibit PDI function and also strongly protect against chemically-induced ferroptosis in cultured neuronal cells. We find that BAZ can directly bind to PDI in vitro and in intact neuronal cells, and also can inhibit PDI’s catalytic activity. Computational modeling analysis reveals that BAZ forms a hydrogen bond with PDI-His256. Inhibition of PDI by BAZ markedly reduces nNOS and iNOS dimerization and NO accumulation, which have recently been shown to play a crucial role in mediating chemically-induced ferroptosis. In addition, the direct antioxidant activity of BAZ may also partially contribute to its protective effect against chemically-induced ferroptosis. Behavioral analysis shows that mice treated with BAZ are strongly protected against kainic acid-induced memory deficits and hippocampal neuronal damage in vivo . In conclusion, the results of this study demonstrate that BAZ is an inhibitor of PDI and can strongly prevent chemically-induced ferroptosis in hippocampal neurons both in vitro and in vivo . These observations offer a novel, estrogen receptor-independent mechanism for the recently-reported neuroprotective actions of BAZ in humans. SIGNIFICANCE STATEMENT Ferroptosis is an iron- and lipid peroxidation-dependent form of regulated cell death. Recent evidence has shown that protein disulfide isomerase (PDI) is an important mediator of chemically-induced ferroptosis and also a new target for ferroptosis protection. We find that bazedoxifene is an inhibitor of PDI, which can strongly protect against chemically-induced ferroptotic neuronal death in vitro and in vivo . Additionally, the molecular mechanism of PDI□bazedoxifene binding interaction is defined. This work provides evidence for an estrogen receptor-independent, PDI-mediated mechanism of neuroprotection by bazedoxifene.
BibTeX
@misc{hao2024strong,
  author = {Xiangyu Hao and Yifan Wang and Yong Xiao Yang and Li‐Xi Liao and Tongxiang Chen and Pan Wang and Xiaojun Chen and Bao Ting Zhu},
  title = {{Strong Protection by Bazedoxifene Against Chemically-Induced Ferroptotic Neuronal Death <i>In Vitro</i> and <i>In Vivo</i>}},
  year = {2024},
  doi = {10.1101/2024.05.26.595988},
  howpublished = {bioRxiv},
}
Figure